Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

699 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Jabbour E, et al. Among authors: konopleva m. Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5. Lancet Haematol. 2018. PMID: 30501869 Free PMC article. Clinical Trial.
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. Weiser MA, et al. Among authors: konopleva m. Cancer. 2004 Mar 15;100(6):1179-85. doi: 10.1002/cncr.20071. Cancer. 2004. PMID: 15022284 Free article.
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Kojima K, et al. Among authors: konopleva m. Blood. 2006 Aug 1;108(3):993-1000. doi: 10.1182/blood-2005-12-5148. Epub 2006 Mar 16. Blood. 2006. PMID: 16543464 Free PMC article.
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ. Yee KW, et al. Among authors: konopleva m. Clin Cancer Res. 2006 Sep 1;12(17):5165-73. doi: 10.1158/1078-0432.CCR-06-0764. Clin Cancer Res. 2006. PMID: 16951235 Clinical Trial.
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Zhang W, et al. Among authors: konopleva m. J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29. J Natl Cancer Inst. 2008. PMID: 18230792 Clinical Trial.
699 results